ARASENS

**Semantic type:** Research Activity

**Definition:** An international, multi-center, double-blind, placebo-controlled phase 3 clinical study investigating the safety and efficacy of darolutamide, an oral antigen receptor inhibitor (ARi), in combination with docetaxel chemotherapy and androgen deprivation therapy (ADT) as treatment for metastatic hormone-sensitive prostate cancer (mHSPC).